Session 2 : ER Positive Braest Cancer and others

ER Positive Braest Cancer and others By Randeep Singh

Chairpersons :

Ramesh Nimmagadda, N K Warrier

Speaker :

Randeep Singh

A phase II trail of neoadjuvant palbociclib , a cyclin -dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative(ER+HER2-)Breast Cancer(BC)

Author: MaCX


Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD L1-positive, estrogen receptor-positive(ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

Author: Rugo HS

Conference: SABCS

High prevalence and clonal hetrogeneity of ESR1 Mutations (MT) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, A randomized Phase II study testing Pictilisib (GDC-0941) in combination with fulvestrant(F) in pts that failed a prior aromatase in-hibitor(AI)

Author: Gendreau S

Conference: SABCS